Who are Protease Inhibitor/ritonavir's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ATV/r, Darunavir (DRV/r), Maraviroc, Darunavir/r, Darunavir/Ritonavir (Prezista), Lopinavir/r, PEP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/protease-inhibitor-ritonavir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Protease Inhibitor/ritonavir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Protease Inhibitor/ritonavir (Protease Inhibitor/ritonavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor combination. Area: Infectious Disease.

phase 3 Protease inhibitor combination HIV protease Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Protease Inhibitor/ritonavir (Protease Inhibitor/ritonavir) — Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia. This combination inhibits HIV protease while ritonavir acts as a pharmacokinetic booster to increase protease inhibitor levels in the bloodstream.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Protease Inhibitor/ritonavir TARGET	Protease Inhibitor/ritonavir	Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia	phase 3	Protease inhibitor combination	HIV protease
ATV/r	ATV/r	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	HIV protease inhibitor (boosted)	HIV protease
Darunavir (DRV/r)	Darunavir (DRV/r)	Community Research Initiative of New England	marketed	HIV protease inhibitor	HIV protease
Maraviroc, Darunavir/r	Maraviroc, Darunavir/r	Catholic University of the Sacred Heart	marketed	Antiretroviral combination (CCR5 antagonist + protease inhibitor)	CCR5 co-receptor (maraviroc); HIV protease (darunavir)
Darunavir/Ritonavir (Prezista)	Darunavir/Ritonavir (Prezista)	Kowa Research Institute, Inc.	marketed	HIV protease inhibitor	HIV protease
Lopinavir/r	Lopinavir/r	Universidade Federal do Rio de Janeiro	marketed	Protease inhibitor	HIV protease
PEP	PEP	Christopher J. McLeod	marketed	Protease inhibitor	HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor combination class)

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · 1 drug in this class
Fundación Huésped · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
University of Chicago · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Protease Inhibitor/ritonavir — Competitive Intelligence Brief. https://druglandscape.com/ci/protease-inhibitor-ritonavir. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab